Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 6, 2024; 12(1): 9-14
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.9
Honeymoon phase in type 1 diabetes mellitus: A window of opportunity for diabetes reversal?
Madhukar Mittal, Pradakshna Porchezhian, Nitin Kapoor
Madhukar Mittal, Pradakshna Porchezhian, Department of Endocrinology and Metabolism, All India Institute of Medical Sciences Jodhpur, Jodhpur 342005, India
Nitin Kapoor, Department of Endocrinology, Diabetes and Metabolism, Christian Medical College and Hospital, Vellore 632004, Tamil Nadu, India
Author contributions: Mittal M conceptualized the manuscript; Porchezhian P and Mittal M wrote the manuscript; Kapoor N provided critical inputs in writing the paper; all authors reviewed and approved the final manuscript.
Conflict-of-interest statement: All the authors have nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Madhukar Mittal, FACE, MD, Professor, Department of Endocrinology and Metabolism, All India Institute of Medical Sciences Jodhpur, Basni Phase 2, Jodhpur 342005, India. mittalspace@gmail.com
Received: October 29, 2023
Peer-review started: October 29, 2023
First decision: November 28, 2023
Revised: December 8, 2023
Accepted: December 14, 2023
Article in press: December 14, 2023
Published online: January 6, 2024
Core Tip

Core Tip: The insulin requirement reduces drastically in the Honeymoon phase or the partial remission phase in type 1 diabetes mellitus (T1DM). Novel pharmacological interventions and immunomodulating therapies in T1DM are being tried specifically in this phase as it may serve as the potential window of opportunity for possible “cure”. It may therefore be clinically relevant to timely identify this phase in these patients.